{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-068637","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.700961+00:00","generated_at":"2026-06-14T05:34:13.088360+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned","bullets":["Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.","Extension is conditioned on achievement of certain milestones included in a compliance plan.","Company plans to advance ELX-02 into pivotal study in Alport Syndrome patients with nonsense mutations.","Plans depend on completing third patient dosing in Phase 2 trial, FDA discussions, and obtaining necessary capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-068637","json":"https://secwatch.observer/filing/0001104659-23-068637.json","markdown":"https://secwatch.observer/filing/0001104659-23-068637.md","text":"https://secwatch.observer/filing/0001104659-23-068637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/0001104659-23-068637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923068637/tm2317998d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:34:13.088360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}